Yale Cancer Center
- 1 min read
- 3 chapters
Related on Lably
Through Cancer
Overview and history
In 1942, Louis S. Goodman, M.D., and Alfred Gilman, Ph.D., in the Yale Department of Pharmacology were the first scientists to use nitrogen mustard, the first alkylating anticancer agent, as chemotherapy to treat cancer in a patient.
During a talk for the Beaumont Medical Club in March 2005, David S. Fischer, M.D. clinical professor of medicine, said, "This was the first patient in the world treated by chemotherapy ... This was proof that cancer could be treated by chemicals."
This initial success led to the development of the world's first multi-center clinical trials in cancer chemotherapy.
Sign in to keep reading
2 more chapters are free with a Lably account.
Clinical care
Clinical care is led by Roy S. Herbst, Chief of Medical Oncology and Associate Director for Translational Research, Yale medical oncologists care for patients in Smilow Cancer Hospital. To organize patient care, Yale Cancer Center and Smilow Cancer Hospital have developed 13 multidisciplinary programs to provide physicians and specialists at Yale Cancer Center with the opportunity to focus their expertise on specific types of cancers.
Research
Yale School of Medicine was home to the country’s first university-based Medical Oncology Section, and its faculty has since pioneered many breakthrough cancer treatments.
Basic research in cancer is a hallmark of Yale Cancer Center, which draws approximately $96 million in cancer research funding to Yale every year.
The research portfolio of Yale Cancer Center comprises six research programs:
- Cancer Immunology
- Cancer Prevention and Control
- Cancer Signaling Networks
- Developmental Therapeutics
- Genetics, Genomics, and Epigenetics
- Radiobiology and Genome Integrity